ERBB3 and neoplasm: The high prevalence of NRG1 expression in HNSCC, while necessary for full ErbB3 activation, may be insufficient to fully predict the anti-tumor activity of an ErbB3-blocking antibody and may explain why the clinical studies to date for anti-ErbB3 antibodies have not proven successful [18].